Global Leading Market Research Publisher QYResearch announces the release of its latest report “Size Exclusion Chromatography Media – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Size Exclusion Chromatography Media market, including market size, share, demand, industry development status, and forecasts for the next few years.
Biopharmaceutical manufacturers and research laboratories face a persistent challenge: separating proteins, antibodies, and other biomolecules by size without high-pressure systems or organic solvents. Traditional purification methods like ion exchange or affinity chromatography rely on binding interactions, requiring harsh elution conditions that can denature sensitive biologics. Size Exclusion Chromatography Media solve this pain point by providing porous granular materials packed within chromatography columns. They have a specific pore size range and are capable of separating molecules based on size. Common media include dextran (e.g., Sephadex), agarose (e.g., Sepharose), polyacrylamide (e.g., Bio-Gel P), and organic polymers. These materials offer excellent chemical stability and mechanical strength, and can be used under varying pH and salt concentration conditions. They are key components for achieving efficient molecular sieving separations. With the explosive growth of monoclonal antibodies (mAbs), gene therapies, and mRNA vaccines, size exclusion chromatography (SEC) has become indispensable for aggregate removal, buffer exchange, and formulation final polishing. Sales volume in 2024 is expected to be 250,000 liters, with an average price of US$400–1,200 per liter.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6096135/size-exclusion-chromatography-media
1. Market Size, Growth Trajectory & Core Keywords
The global market for Size Exclusion Chromatography Media was estimated to be worth US$ 104 million in 2025 and is projected to reach US$ 207 million, growing at a CAGR of 10.5% from 2026 to 2032.
Core industry keywords integrated throughout this analysis include: Size Exclusion Chromatography Media, Agarose-Based SEC, Biopharmaceutical Purification, Protein Aggregate Removal, and Buffer Exchange Resins.
2. Industry Segmentation: Media Chemistry and Application Focus
From a material science stratification viewpoint, SEC media are differentiated by base matrix chemistry and downstream application:
- Agarose-Based SEC Media (Sepharose, Crosslinked Agarose): Dominant segment (approximately 55% of market revenue). Agarose offers excellent biocompatibility, broad pH stability (2–14), and high porosity for large biomolecules (up to 40,000 kDa). Ideal for monoclonal antibody aggregate removal (size range: 150 kDa monomer vs. 300 kDa+ dimer) and plasmid DNA purification. Cytiva’s Superdex and Superose series are industry gold standards. Limitations: lower mechanical strength than polymeric media, limiting flow rates (typically <150 cm/h). Agarose-based media prices: US$600–1,500 per liter.
- Dextran-Based SEC Media (Sephadex, Crosslinked Dextran): Second-largest segment (approximately 25% market revenue). Dextran offers excellent resolution for smaller biomolecules (desalting, peptide separation, nucleotide removal). Lower cost (US$300–600 per liter) and compatible with harsh cleaning (0.5 M NaOH). Limitations: lower stability at high pH (>12) and limited to lower molecular weight applications (<200 kDa). Widely used for buffer exchange (desalting columns) in lab-scale and process development.
- Polyacrylamide-Based SEC Media (Bio-Gel P): Specialized segment (approximately 10% market revenue) offering high resolution for peptide and small protein separation (1–100 kDa). Excellent chemical stability and low nonspecific binding. Limitations: lower flow rates, compressible at larger scales. Primarily used in analytical and research applications.
- Polymer-Based SEC Media (Toyopearl, Polymer Resins): Fastest-growing segment (15% market revenue, 14% CAGR). Rigid polymeric beads (methacrylate, polystyrene-divinylbenzene) offer high mechanical strength, enabling high flow rates (>300 cm/h) and high pressure tolerance. Compatible with organic solvents for polymer analysis. Increasing adoption in commercial bioprocessing (Tosoh’s Toyopearl, Repligen’s Capto). Price premium: US$1,000–2,500 per liter.
Segment by Type
- Agarose-based: Dominant, mAb aggregate removal, high biocompatibility.
- Dextran-based: Desalting, buffer exchange, small molecule separations.
- Polyacrylamide-based: Peptide separation, analytical applications.
- Polymer-based: High flow rate, organic solvent compatibility, bioprocessing.
Segment by Application
- Biopharmaceutical Industry: mAb polishing (aggregate removal), formulation buffer exchange, gene therapy vector purification.
- Scientific Research & Academic Laboratories: Protein analysis, molecular weight determination, desalting.
- Others: Food and beverage analysis, environmental testing, polymer characterization.
3. Recent Industry Data (Last 6 Months) & Policy Drivers
According to new data from the International Society for Pharmaceutical Engineering (ISPE) and bioprocessing market trackers (Q1–Q3 2025):
- Global SEC media revenue increased 12.1% year-over-year, driven by mAb aggregate removal demand (28 new mAb approvals in 2024-2025) and gene therapy manufacturing expansion.
- Agarose-based media maintain dominance (55% share), but polymer-based media are fastest-growing (14.2% CAGR) as manufacturers seek higher throughput.
- Biopharmaceutical industry represents 78% of revenue, with research labs at 18% and others at 4%.
Policy impact: FDA’s 2025 guidance “Quality Considerations for Monoclonal Antibody Products” requires aggregate levels <5% (typically <2% for commercial products), driving demand for high-resolution SEC media for final polishing steps. The European Pharmacopoeia Chapter 2.2.30 (revised January 2026) mandates validated SEC methods for aggregate quantitation in all biologic products, increasing adoption of analytical-grade SEC columns. ICH Q5C (stability testing) revisions require aggregate monitoring throughout shelf life, sustaining SEC media demand in QC laboratories.
4. Technical Challenges & Solution Differentiation
Three persistent technical barriers define competition in SEC media:
- Resolution vs. throughput trade-off: High-resolution SEC requires small particle sizes (10–50 µm) and low flow rates, limiting productivity. Advanced providers like Cytiva and Tosoh offer “multimodal” SEC media (combining size exclusion with weak ion exchange) that improve resolution without sacrificing flow rate, achieving 2–3× higher throughput for aggregate removal. Price premium: 30–50% over standard SEC.
- Cleaning and sanitization compatibility: Bioprocessing SEC columns require regular cleaning (0.5–1 M NaOH) to prevent bioburden and endotoxin accumulation. Agarose-based media tolerate NaOH but degrade with repeated exposure (50–100 cycles). Polymer-based media withstand >300 NaOH cycles, reducing replacement frequency. Purolite and Repligen have launched “high-alkali stability” agarose SEC media (200+ cycles) at 20–30% premium.
- Scale-up reproducibility: SEC performance is highly dependent on column packing quality, which varies from lab to lab. Differentiated suppliers offer pre-packed, ready-to-use SEC columns (lab-scale to process-scale) with guaranteed performance (HETP <2× particle size, asymmetry 0.8–1.5), reducing method transfer time by 60–80%. Sartorius and Bio-Rad have expanded pre-packed column portfolios.
Exclusive industry insight: A 2025 bioprocessing survey (BioPlan Associates, September 2025) found that 38% of manufacturers experienced SEC column packing failures (poor efficiency, channeling) when transitioning from lab to pilot scale, causing 2–4 week delays. This has driven adoption of “single-use” SEC columns (pre-packed, gamma-irradiated, disposable) for clinical manufacturing, eliminating packing validation. Yeasen and Changzhou smart-Lifesciences have launched single-use SEC columns (0.5–10 L bed volume) at 40% premium over reusable columns but with 80% faster changeover. The single-use SEC market is growing at 22% CAGR.
5. User Case Examples (Biopharma vs. Research Applications)
- Case 1 – Biopharmaceutical (mAb aggregate removal): A CDMO producing a commercial monoclonal antibody (10,000 L batch) required final polishing SEC to reduce aggregate from 4% to <1.5%. Using Cytiva’s Superdex 200 agarose-based media in a 200 L column (60 cm diameter, 30 cm bed height), they achieved 98% monomer recovery with aggregate reduced to 1.2%. The column was reused for 80 cycles over 18 months before replacement.
- Case 2 – Research laboratory (protein complex analysis): An academic structural biology lab required separation of a multi-protein complex (450 kDa) from free protein contaminants (50 kDa) for crystallization trials. Using Bio-Rad’s Bio-Gel P-300 polyacrylamide media in a 2.5 cm × 100 cm column, they achieved baseline separation in 3 hours. The purified complex diffracted to 2.8 Å resolution, solving the structure.
6. Competitive Landscape (Selected Key Players)
The SEC media market is moderately concentrated, with a few dominant suppliers and multiple regional and specialty players:
Cytiva (formerly GE Healthcare Life Sciences), Bio-Rad Laboratories, Merck (MilliporeSigma), Tosoh Bioscience, Sartorius Stedim Biotech, Repligen Corporation, Yeasen, Thermo Fisher Scientific, Purolite Life Sciences (an Ecolab company), Avantor, Bio-Works Technologies AB, Agilent Technologies, Phenomenex, Changzhou smart-Lifesciences Biotechnology Co., Ltd., Bioeast.
独家观察 (Exclusive strategic note): Cytiva remains the undisputed market leader (approximately 45% global share) with its Sephadex/Sepharose/Superdex brand family and deep bioprocessing integration. Merck (30% share) competes strongly in research and process development with its EMD Millipore portfolio. The most dynamic competition is in the Asia-Pacific region, where Yeasen, Changzhou smart-Lifesciences, and Bioeast are gaining share at 15–20% price advantages (US$300–700 per liter vs. US$800–1,500 for Cytiva/Merck) for standard agarose and dextran media. However, high-performance polymer-based SEC media remain dominated by Tosoh and Repligen, with Asian suppliers yet to achieve comparable resolution and pressure tolerance. A supply constraint for agarose raw material (from seaweed harvesting) in 2025 caused 3–4 month lead times for standard agarose SEC media, benefiting suppliers with in-house agarose production (Bio-Works, Purolite).
7. Forecast Outlook (2026–2032)
The convergence of continuous manufacturing and single-use SEC technologies will reshape the market by 2028. Over 35% of new bioprocessing facilities are expected to use continuous SEC (simulated moving bed, SMB) rather than batch, reducing media volume requirements by 60–80% but demanding higher mechanical stability (favoring polymer-based media). Biopharma manufacturers should prioritize SEC media suppliers offering (1) high resolution for aggregate removal (2–5 µm particles), (2) cleaning stability (200+ NaOH cycles), (3) pre-packed, single-use options for clinical manufacturing, and (4) regulatory support (drug master files, validation guides). The shift toward gene therapies (AAV, lentivirus) will drive demand for large-pore SEC media (100–200 nm pore size, >10,000 kDa exclusion limit) for vector purification—a segment expected to grow at 18% CAGR.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
